|
Pharmaceutical
policy draft — Must go beyond price control
Published:
Business Line, August 31, 2006
By Pradeep S Mehta
| The
proposed pharmaceutical policy allows
R&D oriented firms to have higher
MAPE, meaning that for the same medicine,
some firms will have 150 per cent margin
while others will have 200 per cent
margin. |
The
draft pharmaceutical policy that proposes to bring
354 drugs under price control has expectedly raised
raging debates in the country. Such a measure
was deemed necessary in view of the Supreme Court
order though it was expected that there would
be resistance from the pharmaceutical lobby.
Indeed,
India had a similar drug price control regime
before as well. However, with decontrol over years,
prices of some medicines soared, so much so that
today for some drugs prices are not only higher
compared to neighbouring countries such as Sri
Lanka and Bangladesh, but even vis-à-vis developed
countries such as Canada and the UK. However,
this is not universal. Some medicines continue
to be available at reasonable prices.
More
medicines under control
The
policy proposes to bring more medicines under
price control but at the same time increase the
Maximum Allowable Post-Manufacturing Expenses
(MAPE) to 150 per cent from the current level
of 100 per cent.
This
is too high and cannot be justified. This also
contradicts the policy of trade margin of 50 per
cent (15 per cent for wholesalers and 35 per cent
for retailers) for generic medicines proposed
in the same policy draft.
Obviously,
many firms should be able sell at lower prices
than the controlled level. The question thus arises:
Is the Government allowing firms to fix prices
at a higher level in the name of price control?
The
Indian experience is that, by and large, the suggested
maximum price invariably becomes the actual selling
price. Hence, for many medicines, there is a risk
that the price control will lead to higher prices.
No
wonder, there is strong opposition on the proposed
price control regime not only from the Department
of Industry, that tends to protect the interests
of the business, but also from the Departments
of Health as well as Consumer Affairs, which seek
to protect the interests of consumers.
No
imposition please
Recently,
the President of the Organisation of Pharmaceutical
Producers of India, had criticised the proposal
arguing that competition should be encouraged
with appropriate monitoring of prices.
One
may not fully agree with this, and regulation
might be necessary. However, regulation should
try to simulate the "effects of competition"
and price control should not be imposed on drugs
where the "effects of competition" already
exist.
It
would be a better idea to put fewer number of
drugs under price control while retaining the
existing level of MAPE of 100 per cent and put
others on the watch list and adopt a threat-based
policy by reserving the right to bring them under
price control any time their prices cross certain
levels. Regulation of drug prices is necessary
not only because it is a different kind of product
that involves issues of life and death for people,
but also because normal market forces do not operate
as consumers do not make the choice.
In
the case of a normal product, consumers make the
choice based on their perception and experiences
of quality and prices.
However,
for medicines, doctors and retailers play an important
role in the purchase decision. As a result, medicines
of same quality and effectiveness could be sold
at higher prices by providing "incentives"
to doctors and pharmacists.
Generics
vs. inventor co prices
In
fact, the proposed policy has indirectly recognised
this by allowing R&D oriented firms to have
higher MAPE. This means, for the same medicine,
some firms will have 150 per cent margin while
others will have 200 per cent. Incidentally, such
problems occur for all medicines, essential and
non-essential.
Nevertheless,
the proposed policy has not spelt out any effective
measures to deal with such problems. True, the
measure of fixing trade margins can deal with
such problems. However, it has been proposed only
for generic medicines, though the problems are
there with all medicines. The issue of trade margin
deserves more attention as it can check the anti-competitive
practices of the retailers who are cartelised
and often force the manufacturers to offer higher
margins. In any case, such cartelised behaviour
must be stopped, as otherwise consumers will be
forced to pay higher prices even if the pharmaceutical
manufacturers are willing to provide them at reasonable
prices.
De-branding
It is also not clear why the Government has not
considered de-branding some generic medicines,
one of the recommendations of the task force headed
by Dr Pronab Sen, Advisor, Perspective Planning,
Planning Commission, though the policy speaks
of promoting generic medicines.
The
proposed Drugs (Price Management and Distribution)
Act is a step in the right direction. It will
also be necessary to promote generic medicines
and competition in the market as the consumers
will be able to buy any brand of medicine without
bothering about the quality and looking at the
prices.
Others
too to be blamed
It
is true that the drug market is not perfectly
competitive due to the peculiarities of the sector.
However,
it is not just the pharmaceutical companies that
are responsible for this. All the other actors
of the health services delivery system, including
doctors, pharmacists, hospitals and diagnostic
clinics, are equally responsible. The Government
thus needs to take a holistic look at the issue
of healthcare and availability of affordable medicine
is only a part of it.
Healthcare
service
For
many people living in the rural areas and for
the poor in the urban areas, the primary issue
is the availability of affordable and "honest"
healthcare services rather than the prices of
medicines. This would require measures other than
price control.
As
for price control, it would be advisable to maintain
the status quo in view of the Supreme Court order.
If more medicines are to be brought under price
control, they should be restricted to a few that
might have seen excessive price increase rather
than all essential drugs.
This
article can also be viewed at URL:
http://www.thehindubusinessline.com/2006/08/31/stories/2006083100291000.htm |